



FIERCE BIOTECH NAMES MERLION PHARMACEUTICALS AS ONE OF THE "FIERCE 15" BIOTECH COMPANIES OF 2007

MerLion Pharmaceuticals is "Fierce," on Leading Edge of Biotech

Singapore – June 6, 2007 – MerLion Pharmaceuticals announced today that it has been included in the annual FierceBiotech "Fierce 15" list, designating it as one of the top biotech companies of 2007. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. MerLion Pharmaceuticals was determined to be one of the "fiercest," proven by their creativity, rapid corporate development, and innovations in the industry.

MerLion Pharmaceuticals has undergone dramatic growth and international expansion in 2006/7. The company has made two strategic acquisitions, closed a landmark US\$30m round of financing and has received regulatory approval to take two novel antibiotics forward into clinical development. The company has expanded its operations into Europe and has retained its leadership position in collaborative natural product-based drug discovery.

"MerLion got started in natural product development when the field was out of fashion, and has benefited from a global comeback. With an international development team and a global perspective, this is one company to watch closely," said John Carroll, Editor of FierceBiotech.

"FierceBiotech is renowned for its advanced understanding of biotechnology companies and the industry as a whole," said Chris Molloy, Chief Operating Officer. "Being selected as a member of the 'Fierce 15' is an honour, and highlights MerLion's potential to make a significant impact in the anti-infectives biotech market."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. The complete list of 'Fierce 15' companies is available in today's issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.

An internationally recognised daily newsletter reaching more than 56,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on drug discovery and clinical trials.

About FierceMarkets

FierceMarkets is a digital business media company serving vertical markets with email newsletters, web sites, and live events. Based in Washington, DC, FierceMarkets publications reach more than 450,000 executives in over 100 countries every business day. Current publications include DailyTechRag (<http://www.dailytechrag.com>), FierceBioResearcher (<http://www.fiercebioresearcher.com>), FierceBiotech (<http://www.fiercebiotech.com>), FierceBioResearcher (<http://www.fiercebioresearcher.com>), FierceCIO (<http://www.fiercecio.com>), FierceDeveloper (<http://www.fiercedeveloper.com>), FierceFinance (<http://www.fiercefinance.com>), FierceGameBiz (<http://www.fiercegamebiz.com>), FierceHealthcare (<http://www.fiercehealthcare.com>), FierceHealthIT (<http://www.fiercehealthit.com>), FierceIPTV (<http://www.fierceiptv.com>), FierceMobileContent (<http://www.fiercemobilecontent.com>), FierceSarbox (<http://www.fiercesarbox.com>), FierceVoIP (<http://www.fiercevoip.com>), FierceWiFi (<http://www.fiercewifi.com>), FierceWireless (<http://www.fiercewireless.com>), and IT-Wireless (<http://www.it-wireless.com>), and The Business VoIP Report (<http://www.businessvoipreport.com>).

Contact: Heather Cox
FierceMarkets, Inc.
202-628-8778 x13
heather@fiercemarkets.com

About MerLion Pharmaceuticals Pte Ltd

MerLion Pharmaceuticals is a privately held international drug discovery and development company headquartered in Singapore.

MerLion has a balanced portfolio of assets that includes several clinical stage candidates, a unique patent position in the area of bacterial virulence, innovative screening approaches and access to the proprietary discovery technologies of its many risk-share partners.

The company's current collaboration partners include Abbott Laboratories, Arpida SA, Astellas Pharma Inc., Boehringer Ingelheim, Cancer Research Technologies Ltd., Dow AgroSciences, Merck Banyu, Merck & Co, Novartis Institute for Tropical Diseases, Pfizer Inc., Sankyo Co Ltd. and Schering-Plough Research Institute.

Contact: Chris Molloy, Chief Operating Officer
Tel : +65 6829 5606
E-mail : enquiry@merlionpharma.com

Visit <http://www.merlionpharma.com> to learn more about MerLion